CRBU
Caribou Biosciences, Inc.
$0.53
-4.86%
2026-10-23
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Key Fundamentals
Forward P/E
-0.98
EPS (TTM)
$-1.08
ROE
-78.3%
Revenue Growth (YoY)
-43.8%
Profit Margin
0.0%
Debt/Equity
27.17
Price/Book
1.34
Beta
2.28
Market Cap
$132.9M
Avg Volume (10D)
1.4M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$1.76
60D Low
$0.44
Avg Volume
2.6M
Latest Close
$0.53
Get breakout alerts for CRBU
Sign up for Breakout Scanner to receive daily notifications when CRBU triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Caribou Biosciences, Inc. (CRBU) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CRBU daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CRBU operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.